Honest framing matters here: human safety data for the CJC-1295 and Ipamorelin stack is limited, so the side-effect picture is drawn from small studies and community reports rather than a robust trial record. Commonly reported effects are local or related to fluid shifts, such as injection-site irritation, water retention, a brief head-rush or flushing, and tingling.[1][2][3]
Reviewed for accuracy · Last reviewed July 7, 2026CJC-1295's main human study reported no serious adverse reactions in a small early-phase setting, and Ipamorelin was described as acceptably tolerated in its Phase 2 postoperative-ileus trial, though that trial did not meet its primary endpoint. Because neither peptide is FDA-approved and both raise the body's own growth hormone, effects such as elevated blood sugar or fluid retention are plausible considerations that are not well characterized at these doses.
Rotating injection sites and watching for persistent numbness or spreading redness are the practical basics. Signs of an allergic reaction are a reason to seek medical attention rather than wait.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.